Navigation Links
Programming cells to home to specific tissues may enable more effective cell-based therapies
Date:10/27/2011

Boston, MA - Stem cell therapies hold enormous potential to address some of the most tragic illnesses, diseases, and tissue defects world-wide. However, the inability to target cells to tissues of interest poses a significant barrier to effective cell therapy. To address this hurdle, researchers at Brigham and Women's Hospital (BWH) have developed a platform approach to chemically incorporate homing receptors onto the surface of cells. This simple approach has the potential to improve the efficacy of many types of cell therapies by increasing the concentrations of cells at target locations in the body. These findings are published online in the journal Blood on Oct. 27, 2011.

For this new platform, researchers engineered the surface of cells to include receptors that act as a homing device. "The central hypothesis of our work is that the ability of cells to home to specific tissues can be enhanced, without otherwise altering cell function," said corresponding author Jeffrey M. Karp, PhD, co-director of the Regenerative Therapeutics Center at BWH and a principal faculty member of the Harvard Stem Cell Institute. "By knowing the 'zip code' of the blood vessels in specific tissues, we can program the 'address' onto the surface of the cells to potentially target them with high efficiencies."

While conventional cell therapies that include local administration of cells can be useful, they are typically more invasive with limited potential for multiple doses. "You can imagine, that when the targeted tissue is cardiac muscle, for example to treat heart attacks or heart failure, injecting the cells directly into the heart can be an invasive procedure and typically this approach can only be performed once," said Dr. Karp, also an assistant professor at Harvard Medical School and affiliate faculty Harvard-MIT Division of Health Sciences and Technology.

Using the platform the researchers created, the cells are prepared to travel directly to the area of interest after being injected through a common and much less invasive intravenous infusion method. "These engineered cells may also be more effective because multiple doses can be administered" stated Debanjan Sarkar, PhD, previously a postdoctoral fellow in Dr. Karp's lab and now an Assistant Professor of Biomedical Engineering at the State University of New York, University at Buffalo.

"The necessity for a more effective delivery approach stems from the potential diseases cell therapy may address," said Dr. Karp, noting that the approach can be used to systemically target bone producing cells to the bone marrow to treat osteoporosis, cardiomyocytes to the heart to treat ischemic tissue, neural stem cells to the brain to treat parkinson's disease, or endothelial progenitor cells to sites of peripheral vascular disease to promote formation of new blood vessels.

The researchers concluded that, as the understanding of the mechanisms of cell trafficking grows, the ability to improve homing to specific tissues through engineered approaches should significantly enhance cell therapy by reducing the invasiveness of local administration, permitting repeat dosing, and potentially reducing the number of cells required to achieve a therapeutic effect, ultimately providing better outcomes for patients.
'/>"/>

Contact: Holly Brown-Ayers
hbrown-ayers@partners.org
617-534-1603
Brigham and Women's Hospital
Source:Eurekalert  

Related medicine news :

1. OASIS Recognized for Brain Fitness Programming
2. Adritech Software Releases Website Realizer, a Website Builder to Create Websites without Any Programming Knowledge
3. University of Michigan Health System earns major grant to expand childhood obesity programming
4. Fetal programming of disease risk to next generation depends on parental gender
5. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
6. New study suggests stem cells sabotage their own DNA to produce new tissues
7. Attacking cancer cells with hydrogel nanoparticles
8. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
9. Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery
10. New tool illuminates connections between stem cells and cancer
11. Bitter melon extract attacks breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Programming cells to home to specific tissues may enable more effective cell-based therapies
(Date:7/24/2017)... ... July 24, 2017 , ... Peruvian Ayahuasca retreat, ... be awarded annually to and divided between two full-time university students enrolled in ... Amazonian plant medicine. To apply for the scholarship, students are asked to submit ...
(Date:7/24/2017)... ... 24, 2017 , ... The Topricin Companies, formerly Topical Biomedics, ... revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. , ... skin conditions, including cancer. In the short term, overexposure to sun, wind ...
(Date:7/24/2017)... Switzerland (PRWEB) , ... July 24, 2017 , ... Anyone ... to weigh a watermelon, nor would a pharmacist using that same scale to dispense ... risk someone’s health. , These illustrations show why it is important to have ...
(Date:7/24/2017)... ... 2017 , ... Paul Vitenas, MD, FACS is excited to report that he ... attend Allergan’s recent meeting with their Plastics Advisory Board. As one of the top ... bringing a newly defined structure to the aesthetics market. Dr. Vitenas , along ...
(Date:7/24/2017)... ... ... Summer storms are inevitable as weather temperatures in Philadelphia climb. These ... tree damage requiring emergency tree service. Giroud Tree and Lawn provides ... hazardous tree removal. , “A summer storm is like a bully on ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on the development of ... approval from the Israel Securities Authority to dual-list its common ... stock will commence trading on the TASE on July 12, ... capitalization of the Company, it is expected that Oramed will ...
(Date:7/5/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... announced that it has reached an agreement with WAVI ... to modify its existing credit facility effective June 30, ... agreed to exchange its existing $4.25 million credit facility, ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: